Serum protease inhibitor - Ulinastatin in the complex therapy of severe acute pancreatitis complicated by sepsis

dc.contributor.authorAvakov V.E
dc.contributor.authorIbrahimov N.K
dc.contributor.authorGaziev Z.T
dc.contributor.authorRamazanova Z.F
dc.contributor.authorMuralimova R.S
dc.contributor.authorMurotov TMN
dc.date.accessioned2026-01-01T21:15:30Z
dc.date.issued2022-12-14
dc.description.abstractAcute pancreatitis is an acute inflammation of the pancreas that often leads to pancreatic necrosis and is the cause of death in 40% to 70% of patients. [1] Given the severity of this disease and the insufficient effectiveness of generally accepted methods of treatment, we studied the effectiveness of the drug Ulinastatin (serum protease inhibitor) in the complex therapy of acute pancreatic necrosis, complicated by diffuse purulent peritonitis and sepsis.
dc.formatapplication/pdf
dc.identifier.urihttps://geniusjournals.org/index.php/erb/article/view/2854
dc.identifier.urihttps://asianeducationindex.com/handle/123456789/66900
dc.language.isoeng
dc.publisherGenius Journals
dc.relationhttps://geniusjournals.org/index.php/erb/article/view/2854/2440
dc.sourceEurasian Research Bulletin ; Vol. 15 (2022): ERB; 140-148
dc.source2795-7675
dc.subjectacute pancreatitis
dc.subjectinhibitor
dc.subjectenzymatic autolysis,
dc.subjectSOFA
dc.titleSerum protease inhibitor - Ulinastatin in the complex therapy of severe acute pancreatitis complicated by sepsis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Article

item.page.files

item.page.filesection.original.bundle

pagination.showing.labelpagination.showing.detail
loading.default
thumbnail.default.alt
item.page.filesection.name
ve_2022_serum_protease_inhibitor_-_ulinastatin_i.pdf
item.page.filesection.size
341.06 KB
item.page.filesection.format
Adobe Portable Document Format

item.page.collections